- Home
- Live Blog
- Breaking News
- Top Headlines
- Cities
- NE News
- Sentinel Media
- Sports
- Education
- Jobs
NEW YORK: US-based life sciences company Emergent BioSolutions Inc. has entered into an estimated $87 million deal to be the US manufacturing partner for AstraZeneca's COVID-19 vaccine candidate developed by the Oxford University.
The pact announced on Thursday comes after the US government booked about 300 million doses of the potential vaccine with a $1.2 billion deal with AstraZeneca last month.
"By partnering with leading innovators like AstraZeneca, Emergent is playing a critical role in increasing the world's chances of having a safe and effective COVID-19 vaccine," Robert G Kramer, President and CEO of Emergent BioSolutions said in a statement.
AstraZeneca's vaccine candidate is one of several candidates supported by Operation Warp Speed (OWS), the US government's programme to accelerate the development, manufacturing, and distribution of COVID-19 medical countermeasures that aims to have substantial quantities of a safe and effective vaccine available for Americans by January 2021. (IANS)
Also watch: Morning Bulletin | 12th June 2020